Granted. But they had no choice but to raise the A/S to be able to pay off this note. They'll also need to raise money to conduct clinical trials, if in fact Escozine is approved for IND status. We might see more noteholders if it does get approved. But there's no hiding it, they are diluting. But they do at least have decent reasons to raise capital.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.